Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Oct 9, 2018

Keywords

ClinConnect Summary

The Liquid Biopsy Evaluation and Repository Development trial at Princess Margaret Cancer Centre is studying a new way to understand and monitor different types of cancer, including breast, lung, and colorectal cancers, among others. Researchers are focusing on using "liquid biopsies," which involve taking a simple blood sample to look for tiny pieces of DNA and RNA released by tumors into the bloodstream. This method is non-invasive and can provide valuable information about a patient's cancer status before diagnosis, during treatment, and as the disease progresses.

To participate in this trial, you need to be at least 18 years old and either have a confirmed diagnosis of cancer or be considered high-risk for developing cancer due to your family history or specific genetic factors. All participants must give their consent to join the study. If you enroll, you can expect to provide blood samples at different times throughout your treatment journey, helping researchers learn more about how to better manage and treat cancer in the future. There's no exclusion based on health conditions, so if you meet the inclusion criteria, you can participate in this important research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
• • 2. Patient must be ≥ 18 years old.
• • 3. All patients must have signed and dated an informed consent form for this LIBERATE study.
• • 4. If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence.
• Exclusion Criteria:
• • None